[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Angola\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100461229","phase-3-promoting-utilization-and-safety-of-hydroxyurea-using-precision-in-africa-100461229",false,"NCT05285917","Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa","BrUOG 419 - Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSHUP)","PUSHUP","Inclusion Criteria:\n\n* Diagnosis of sickle cell anemia (HbSS or HbS\u002FB0-thalassemia)\n* Age 6 months- 12 years of age at enrollment\n* Parent or guardian willing and able to provide written or informed consent\n* Weight ≥ 7.5 kg (temporary exclusion)\n\nExclusion Criteria:\n\n* Splenomegaly with evidence of hypersplenism as defined by platelet count \\\u003C150,000, hemoglobin \\\u003C5 g\u002FdL or absolute neutrophil count \\\u003C1.0 x10\\^9\u002FL\n* Hydroxyurea use within the past 6 months\n* Blood transfusion within the past 6 months (temporary exclusion)\n* Pregnancy\n* Pre-existing severe hematologic toxicity, as defined by platelet count \\\u003C80,000, hemoglobin \\\u003C4 regardless of ANC; hemoglobin \\\u003C6 AND ARC \\\u003C100; hemoglobin \\\u003C7 AND ARC \\\u003C80 x10\\^9\u002FL (temporary exclusion)","ALL","6 Months","12 Years",{"count":21,"type":22},400,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Sickle cell anemia (SCA) is among the world's most common and devastating blood disorders, affecting more than 300,000 newborns per year. Most infants with SCA are born in the low-resource settings of sub- Saharan Africa, where an estimated 50-90% will die before 5 years of age due to lack of early diagnosis and appropriate care. Hydroxyurea is a safe and effective once-daily oral medication that has become the standard of care for the treatment of children with SCA in high-resource settings. There is now a growing body of evidence to support the safety and clinical benefits of hydroxyurea for the treatment of SCA in sub-Saharan Africa. The requirement for frequent laboratory monitoring, uncertainties about appropriate, most effective dosing, and the concern for hematologic laboratory toxicities, however, will continue to limit widespread hydroxyurea utilization and real-world effectiveness. The investigators have recently developed and prospectively evaluated an individualized, pharmacokinetics-guided hydroxyurea dosing strategy for children with SCA that has demonstrated optimal clinical and laboratory benefits with minimal toxicity. In this research study, the investigators aim to extend this precision medicine approach to Africa.",[28,29],"Sickle Cell Anemia in Children","Sickle Cell Disease","RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":34},"2023-11-15",{"date":38,"type":22},"2027-09-01",{"name":40,"class":41},"Brown University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100604147","phase-4-moxidectin-versus-ivermectin-as-mass-drug-administration-for-the-control-of-onchocerciasis-and-other-neglected-tropical-diseases-100604147","NCT07145736","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial","EKAIO","Inclusion Criteria:\n\n* Male or female children and adults\n* Residents in the villages selected for MDA treatment\n\nExclusion Criteria:\n\n* Arm 1 (ivermectin): children under the age of 5 and\u002For under 90 cm of height\n* Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height\u002F5 years of age and above).\n* Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age\n* Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)\n* Know allergy to ivermectin or moxidectin\n* Attending other clinical trials during the study\n* Pregnant\n* Arm 2 (moxidectin): Women planning to become pregnant in the 3 months post-treatment\n* Refusal to receive one or both study drugs, i.e. participants in villages allocated to receive moxidectin who refuse to receive moxidectin will be given the option to receive ivermectin; if they refuse to receive both drugs they will be excluded from the MDA altogether\n* Has an illness that makes them too sick or weak to get out of bed\n* Currently hospitalized",true,"5 Years",{"count":54,"type":22},52000,[56],"PHASE4","This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease. The study also explores how these treatments affect other infections common in the region, including intestinal worms (soil-transmitted helminths) and scabies.\n\nThe trial aims to answer the following key questions:\n\n* How do moxidectin and ivermectin compare in reducing the prevalence (how common the disease is) and intensity (amount of parasites per person) of onchocerciasis in the community?\n* Do the treatments differ in their effect on the prevalence and intensity of soil-transmitted helminths and the prevalence of scabies?\n* Does moxidectin reduce transmission of onchocerciasis more effectively than ivermectin, based on genetic testing of parasites in people and lab testing of the blackflies that carry the infection?\n* How many more years of treatment would be needed to reach elimination with each drug, based on mathematical disease modelling?\n* How do communities feel about receiving moxidectin versus ivermectin, and what factors help or make it harder to carry out MDA programs with moxidectin versus ivermectin?\n\nThe study takes place in Bié Province, Angola, and involves 20 groups of villages randomly assigned to receive either moxidectin or ivermectin once a year for four years. Prior to every round of MDA, researchers will collect skin, stool and blood samples from a sample of the people living in the study area. We believe the results will help guide global policy on the use of moxidectin in efforts to eliminate onchocerciasis and control related diseases.",[59,60,61,62,63],"Onchocerciasis","Ascaris Lumbricoides Infection","Trichuris Trichiura; Infection","Hookworm Infections","Scabies","2025-11-18",{"date":66,"type":34},"2025-11-21",{"date":68,"type":34},"2025-08-04",{"date":70,"type":22},"2029-06-30",{"name":72,"class":73},"Kirby Institute","OTHER_GOV",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100500658","study-of-the-role-of-genetic-modifiers-in-hemoglobinopathies-100500658","NCT05799118","Study of the Role of Genetic Modifiers in Hemoglobinopathies","INHERENT","Inclusion Criteria:\n\n* Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered.\n* Age ≥ 2 years old at the time of the collection of the phenotypic data.\n* There will be no limits on study participants in terms of gender, ethnicity, morbidities.\n\nExclusion Criteria:\n\n* Patients treated with stem cell transplantation or genetic therapy.\n* Age \\\u003C 2 years old at the time of the collection of the phenotypic data.\n* Patient or legal representative for minors unwilling or unable to give consent.","2 Years",{"count":83,"type":22},30000,"OBSERVATIONAL","This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).",[29,87,88,89],"Thalassemia, Beta","Thalassemia Alpha","Hemoglobinopathies",[91,92,93,94],"GWAS","thalassemia","sickle cell disease","genetic modifiers","2024-03-19",{"date":97,"type":34},"2024-03-20",{"date":99,"type":34},"2022-10-01",{"date":101,"type":22},"2027-09-30",{"name":103,"class":41},"Cyprus Institute of Neurology and Genetics",26,""]